JP7650074B2 - 眼疾患を治療するための組成物及び方法 - Google Patents

眼疾患を治療するための組成物及び方法 Download PDF

Info

Publication number
JP7650074B2
JP7650074B2 JP2021557369A JP2021557369A JP7650074B2 JP 7650074 B2 JP7650074 B2 JP 7650074B2 JP 2021557369 A JP2021557369 A JP 2021557369A JP 2021557369 A JP2021557369 A JP 2021557369A JP 7650074 B2 JP7650074 B2 JP 7650074B2
Authority
JP
Japan
Prior art keywords
peptide
salt
seq
unit dose
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021557369A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527276A5 (https=
JP2022527276A (ja
Inventor
ニランジャン ビー． パンディ
Original Assignee
アスクレピクス セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アスクレピクス セラピューティクス インコーポレイテッド filed Critical アスクレピクス セラピューティクス インコーポレイテッド
Publication of JP2022527276A publication Critical patent/JP2022527276A/ja
Publication of JP2022527276A5 publication Critical patent/JP2022527276A5/ja
Application granted granted Critical
Publication of JP7650074B2 publication Critical patent/JP7650074B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2021557369A 2019-03-26 2020-03-26 眼疾患を治療するための組成物及び方法 Active JP7650074B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962824017P 2019-03-26 2019-03-26
US62/824,017 2019-03-26
PCT/US2020/024972 WO2020198481A1 (en) 2019-03-26 2020-03-26 Compositions and methods for treating ocular disease

Publications (3)

Publication Number Publication Date
JP2022527276A JP2022527276A (ja) 2022-06-01
JP2022527276A5 JP2022527276A5 (https=) 2023-03-28
JP7650074B2 true JP7650074B2 (ja) 2025-03-24

Family

ID=72609544

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021557369A Active JP7650074B2 (ja) 2019-03-26 2020-03-26 眼疾患を治療するための組成物及び方法

Country Status (12)

Country Link
US (1) US12540171B2 (https=)
EP (1) EP3946418A4 (https=)
JP (1) JP7650074B2 (https=)
KR (1) KR20210146352A (https=)
CN (1) CN113710264A (https=)
AU (1) AU2020248438A1 (https=)
CA (1) CA3134816A1 (https=)
EA (1) EA202192607A1 (https=)
IL (1) IL286625A (https=)
MX (1) MX2021011727A (https=)
WO (1) WO2020198481A1 (https=)
ZA (1) ZA202107235B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
CN117126233A (zh) * 2022-05-20 2023-11-28 杭州禾泰健宇生物科技有限公司 一种类肽化合物及其应用
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018067646A1 (en) 2016-10-04 2018-04-12 Asclepix Therapeutics, Llc Compounds and methods for activating tie2 signaling
WO2018208829A1 (en) 2017-05-08 2018-11-15 Asclepix Therapeutics, Llc Biodegradable microparticles for sustained delivery of anti-angiogenic peptide
JP2018535224A (ja) 2015-11-19 2018-11-29 アスクレピクス セラピューティクス エルエルシー． 抗血管新生、抗リンパ管新生及び抗浮腫特性を有するペプチド及びナノ粒子製剤
WO2019028427A1 (en) 2017-08-03 2019-02-07 Asclepix Therapeutics, Llc. METHODS OF IDENTIFYING AND PREPARING PHARMACEUTICAL AGENTS TO ACTIVATE TIE2 RECEPTOR

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2015781A4 (en) * 2005-09-12 2009-12-23 Univ Johns Hopkins COMPOSITIONS HAVING ANTIANGIOGENIC ACTIVITY AND USES THEREOF
EP2649095B1 (en) * 2010-12-10 2021-10-06 Aleksander S. Popel Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases
JP6470740B2 (ja) * 2013-06-07 2019-02-13 ザ ジョンズ ホプキンス ユニバーシティ 血管新生およびリンパ管新生依存性疾患の処置のための生体模倣ペプチドおよび生分解性送達プラットフォーム

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018535224A (ja) 2015-11-19 2018-11-29 アスクレピクス セラピューティクス エルエルシー． 抗血管新生、抗リンパ管新生及び抗浮腫特性を有するペプチド及びナノ粒子製剤
WO2018067646A1 (en) 2016-10-04 2018-04-12 Asclepix Therapeutics, Llc Compounds and methods for activating tie2 signaling
WO2018208829A1 (en) 2017-05-08 2018-11-15 Asclepix Therapeutics, Llc Biodegradable microparticles for sustained delivery of anti-angiogenic peptide
WO2019028427A1 (en) 2017-08-03 2019-02-07 Asclepix Therapeutics, Llc. METHODS OF IDENTIFYING AND PREPARING PHARMACEUTICAL AGENTS TO ACTIVATE TIE2 RECEPTOR

Also Published As

Publication number Publication date
KR20210146352A (ko) 2021-12-03
AU2020248438A1 (en) 2021-10-28
ZA202107235B (en) 2023-10-25
WO2020198481A1 (en) 2020-10-01
CA3134816A1 (en) 2020-10-01
EP3946418A4 (en) 2023-02-22
US12540171B2 (en) 2026-02-03
EA202192607A1 (ru) 2022-03-03
US20230054032A1 (en) 2023-02-23
CN113710264A (zh) 2021-11-26
IL286625A (en) 2021-12-01
MX2021011727A (es) 2022-01-24
JP2022527276A (ja) 2022-06-01
EP3946418A1 (en) 2022-02-09

Similar Documents

Publication Publication Date Title
US11738064B2 (en) Pharmaceutical composition for preventing and treating eye diseases, containing as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused
CN109715189B (zh) 靶向VE-PTP(HPTP-β)的人源化单克隆抗体
JP5739908B2 (ja) 血管形成関連の眼疾患の処置のための組成物および方法
JP7650074B2 (ja) 眼疾患を治療するための組成物及び方法
US20210393738A1 (en) Method For Treating Angiogenic Eye Disorders Using Vegf Antagonists
CN107427549B (zh) 用于抑制血管生成的肽
JP2016522248A (ja) ポリープ状脈絡膜血管症の治療
KR20220062279A (ko) 안질환의 치료 방법
TW201904610A (zh) 用於治療新生血管型青光眼之非抗體vegf拮抗劑
EP4251204A1 (en) Vegf antagonist for use in methods for treating ocular diseases
JP6944463B2 (ja) 眼疾患の治療のための組成物及び方法
KR20140130725A (ko) 트롬빈 유래 펩타이드를 포함하는 망막증 또는 녹내장 치료용 조성물
KR20220051791A (ko) Fas 신호전달 억제용 펩타이드를 포함하는 황반변성 예방 또는 치료용 조성물
EP4398926A2 (en) Treatment of geographic atrophy
WO2024153189A1 (zh) 一种复方制剂及其应用
CN121194795A (zh) 膜联蛋白a5蛋白质与抗vegf药剂作为组合疗法用于治疗黄斑水肿或视网膜静脉阻塞
CN119907677A (zh) 在治疗黄斑水肿或视网膜静脉阻塞中使用的单体膜联蛋白a5
CA3253955A1 (en) ANNEXIN A5 MONOMER FOR USE IN THE TREATMENT OF MACULAR EDEMA OR RETINAL VEIN OCCUSION

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230317

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230317

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240802

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241120

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250304

R150 Certificate of patent or registration of utility model

Ref document number: 7650074

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150